Safety of Antiepileptic Withdrawal in Long Term Video-EEG Monitoring

NCT ID: NCT02679846

Last Updated: 2021-01-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

1567 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-02-19

Study Completion Date

2020-12-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

SAVE is a stratified cluster-randomised controlled, parallel group, open-label trial, with Epileptic Monitoring Unit (EMU) as the units of randomisation and patients as the unit of analysis.

The focus of research is the management of AntiEpileptic Drugs (AEDs) withdrawal during long term Video EEG (VEEG) monitoring in patients with drug resistant seizures. This non-standardised medical practice, which aims at promoting the occurrence of seizures during the time limit of the monitoring period, exposes patients to significant risks which should be minimised by harmonisation of practice and a standardised protocol of AEDs withdrawal.

SAVE will assess the impact of a standardised protocol of AEDs withdrawal during long-term VEEG monitoring on the frequency of seizure-related serious adverse events occurring during these monitorings and on the ability to obtain VEEG recording of seizures within appropriate time limits.

10 of the 22 EMUs will be randomised to the group where the standardised protocol of AEDs withdrawal will be used systematically, while the other ten EMUs will continue their current non-standardised practice of AEDs withdrawal, and will serve as a control group.

The setting of the study will include a 6 months evaluation phase, prior to randomisation, during which the organisational characteristics, baseline EMUs' activity, current management of AEDs withdrawal, and rate of Serious Adverse Events (SAEs) of each participating center will be evaluated.

The standardised study protocol of AEDs withdrawal has been defined on the basis of a systematic review of all relevant publications in the field.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Epilepsy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standardized protocol of AEDs withdrawal

The standardized protocol of AEDs withdrawal will be implemented and applied to all inpatients

Group Type EXPERIMENTAL

Standardized protocol

Intervention Type OTHER

The standardized protocol of AEDs withdrawal will be implemented and applied to all inpatients

Current practice

Centers will continue their current practice

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Standardized protocol

The standardized protocol of AEDs withdrawal will be implemented and applied to all inpatients

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female suffering from drug-resistant epilepsy
* Age ≥ 6 years old
* Inpatient in one of the participating EMUs for recording seizure during long-term VEEG monitoring (≥ 48 hours)
* Patient who gave its written informed consent to participate to the study, or for children, whose minimum one of parents had given its written informed consent

Exclusion Criteria

* Age \< 6 years old
* Inpatient in one of the participating EMUs for performing short-term VEEG monitoring (\<48 hours)
* Pregnant or breastfeeding woman
Minimum Eligible Age

6 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospices Civils de Lyon

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sylvain RHEIMS, MD

Role: PRINCIPAL_INVESTIGATOR

Service de Neurologie Fonctionnelle et d'Epileptologie et Institut des Epilepsies

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hôpital Nord

Amiens, , France

Site Status

CHU d'Angers

Angers, , France

Site Status

Hôpital R. Pellegrin

Bordeaux, , France

Site Status

Hôpital HFME

Bron, , France

Site Status

Hôpital P. Wertheimer

Bron, , France

Site Status

Hôpital Général

Dijon, , France

Site Status

Hôpital Michallon

Grenoble, , France

Site Status

Hôpital R. Salengro

Lille, , France

Site Status

Hôpital de La Timone

Marseille, , France

Site Status

Hôpital G. de Chauliac

Montpellier, , France

Site Status

Hôpital Central

Nancy, , France

Site Status

Hôpital Pasteur

Nice, , France

Site Status

La Pitié Salpétrière

Paris, , France

Site Status

Hôpital Necker

Paris, , France

Site Status

Fondation Ophtalmologique Adolphe de Rothschild

Paris, , France

Site Status

Hôpital Robert Debré

Paris, , France

Site Status

Hôpital Pontchaillou

Rennes, , France

Site Status

Hôpital Ch. Nicolle

Rouen, , France

Site Status

Hôpital Nord

Saint-Etienne, , France

Site Status

Hôpital Hautepierre

Strasbourg, , France

Site Status

La Teppe

Tain-l'Hermitage, , France

Site Status

Hôpital Paul Riquet

Toulouse, , France

Site Status

CHU Bretonneau

Tours, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2014-A01460-47

Identifier Type: OTHER

Identifier Source: secondary_id

2014-852

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.